drugset / Trial / NCT05251766
Nab-paclitaxel Compared With Docetaxel in the Neoadjuvant Chemotherapy Breast Cancer
Non-randomizedParallel-groupTriple-blindTreatment
Summary
Comparison of docetaxel and Nab-paclitaxel in neoadjuvant chemotherapy for breast cancer
Timeline
- Start
- 2022-04-20
- Primary completion
- 2022-12-30
- Completion
- 2023-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Docetaxel | Small molecule | 75 mg/m2 | — |
| Subject | Nab-paclitaxel | Small molecule | 260 mg/m2 | — |